Ozempic’s success and popularity have led to an increase in interest in comparable weight-loss medications.
The Health Science Center in San Antonio is currently working on the development of one of those medications.
A new medication to aid in weight loss has been developed by researchers Madesh Muniswamy, a professor of medicine from UT Health San Antonio, being one of them.
In mice given a lifelong high-sugar, high-fat Western diet, the small-molecule medication CPACC prevents weight gain and unfavorable liver changes.
Muniswamy said that “When we give this drug to mice for a short time, they begin losing weight. They all become slim.”
On February 27, Muniswamy and colleagues from Cornell University and the University of Pennsylvania published their research in the journal Cell Reports.
The senior author was Muniswamy, the Center for Mitochondrial Medicine director.
The research team’s initial focus was on the effects of magnesium on metabolism, or the generation and use of energy in cells.
The fourth-most prevalent element in the body, magnesium, is crucial for maintaining good health because it helps to build bones and regulate blood pressure and blood sugar levels.
But, as it turns out, too much magnesium slows down the production of energy.
MRS2, a gene that facilitates magnesium transport into mitochondria, the cell’s power plant, was deleted, and this improved the metabolism of sugar and fat, making the mice thinner.
“Since the drug target is conserved right between bacteria and humans, we anticipate pretty similar clinical outcomes in humans. Gene deletion of this channel in a mouse model causes hypermetabolism and more energy production,” Muniswamy shared via Express-News in an email.
The lab mice were used to test whether or not the calorie-dense, sugary, and fatty diet consumed by Western populations caused long-term dietary stress in them. Obesity, type 2 diabetes, and cardiovascular complications are frequently brought on by this stress. The liver and the fat tissues of the rodents showed zero signs of fatty liver disease, another dietary complication.
Muniswamy also wrote that “We anticipate this drug would alleviate obesity, cardiometabolic disease, fatty liver disease, and hepatocellular carcinoma,” pointing out that the study identified zero side effects in the early phases.
However, in order to completely rule out off target effects, researchers still intend to carry out additional testing.
Due to the medication’s ability to lower the risk of cancer and cardiovascular disease, a significant impact is anticipated. Prior to conducting human clinical trials, the medication will continue to go through preclinical research.